Evotec SE (EVO)
NASDAQ: EVO · Real-Time Price · USD
1.955
-0.005 (-0.26%)
Aug 17, 2026, 11:40 AM EDT - Market open
Evotec SE Revenue
Evotec SE had revenue of 143.48M EUR in the quarter ending June 30, 2026, a decrease of -16.21%. This brings the company's revenue in the last twelve months to 717.28M, down -7.72% year-over-year. In the year 2025, Evotec SE had annual revenue of 788.37M, down -1.08%.
Revenue (ttm)
717.28M EUR
Revenue Growth
-7.72%
P/S Ratio
0.87
Revenue / Employee
160,790 EUR
Employees
4,461
Market Cap
709.19M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 788.37M | -8.59M | -1.08% |
| Dec 31, 2024 | 796.97M | 15.54M | 1.99% |
| Dec 31, 2023 | 781.43M | 29.98M | 3.99% |
| Dec 31, 2022 | 751.45M | 133.41M | 21.59% |
| Dec 31, 2021 | 618.03M | 117.11M | 23.38% |
| Dec 31, 2020 | 500.92M | 54.49M | 12.20% |
| Dec 31, 2019 | 446.44M | 71.03M | 18.92% |
| Dec 31, 2018 | 375.41M | 111.64M | 42.33% |
| Dec 31, 2017 | 263.77M | 99.26M | 60.34% |
| Dec 31, 2016 | 164.51M | 36.83M | 28.85% |
| Dec 31, 2015 | 127.68M | 38.18M | 42.66% |
| Dec 31, 2014 | 89.50M | 3.56M | 4.14% |
| Dec 31, 2013 | 85.94M | -1.33M | -1.52% |
| Dec 31, 2012 | 87.27M | 7.14M | 8.91% |
| Dec 31, 2011 | 80.13M | 24.87M | 45.00% |
| Dec 31, 2010 | 55.26M | 12.58M | 29.47% |
| Dec 31, 2009 | 42.68M | 3.07M | 7.75% |
| Dec 31, 2008 | 39.61M | -14.77M | -27.16% |
| Dec 31, 2007 | 54.38M | -30.30M | -35.78% |
| Dec 31, 2006 | 84.68M | 4.90M | 6.14% |
| Dec 31, 2005 | 79.79M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 915.45M |
| Collegium Pharmaceutical | 808.21M |
| Pacira BioSciences | 746.16M |
| Amphastar Pharmaceuticals | 730.02M |
| Ironwood Pharmaceuticals | 389.32M |
| Evolus | 316.49M |
| Canopy Growth | 206.77M |
| Glass House Brands | 181.40M |
EVO News
- 4 days ago - Evotec Reports Second Quarter And First Half 2026 Results, Updates Full-Year Outlook; Stock Down - Nasdaq
- 4 days ago - Evotec SE Quarterly report: Q2 2026 - Filings
- 11 days ago - Evotec enters R&D collaboration with Odyssey Therapeutics - TheFly
- 11 days ago - Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - PRNewsWire
- 14 days ago - Niagen Bioscience selects Evotec to advance development for NB4168 - TheFly
- 14 days ago - Niagen Bioscience, Inc: Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168 - Finanz Nachrichten
- 14 days ago - Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168 - Business Wire
- 16 days ago - Evotec SE Slides: Company presentation - Filings